Reprint of: Nanocarrier systems for oral drug delivery: Do we really need them?

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 1, 2013, Pages 2-7

  Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Gastrointestinal stability; Nanocarrier systems; Nanoparticles; Oral drug delivery; Permeation; Solubility

Indexed keywords

NANOCARRIER; NANOCRYSTAL; SOLID LIPID NANOPARTICLE;

CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG UPTAKE; GASTROINTESTINAL TRACT; HUMAN; MUCUS; NANOEMULSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 84885035190     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.06.011     Document Type: Review

References (39)

1. Ahuja, G., Pathak, K., 2009. Porous carriers for controlled/modulated drug delivery. Indian J. Pharm. Sci. 71, 599-607.
2. Akiyama, Y., Nagahara, N., Nara, E., Kitano, M., Iwasa, S., Yamamoto, I., Azuma, J., Ogawa, Y., 1998. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. J. Pharm. Pharmacol. 50, 159-166. (Pubitemid 28102572)
3. Albrecht, K., Bernkop-Schnürch, A., 2007. Thiomers: forms, functions and applications to nanomedicine. Nanomedicine (Lond.) 2, 41-50. (Pubitemid 46845775)
4. Albrecht, K., Greindl, M., Deutel, B., Kremser, C., Wolf, C., Talasz, H., Stollenwerk, M.M., Debbage, P., Bernkop-Schnürch, A., 2008. In vivo investigation of thiomerpolyvinylpyrrolidon nanoparticles using magnetic resonance imaging. J. Pharm. Sci. 99, 2008-2017.
5. Attivi, D., Ajana, I., Astier, A., Demoré, B., Gibaud, S., 2010. Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev. Ind. Pharm. 36, 421-427.
6. Bandivadeka, M.M., Pancholi, S.S., Kaul-Ghanekar, R., Choudhari, A., Koppikar, S., 2012. Self-microemulsifying smaller molecular volume oil (Capmul MCM) using non-ionic surfactants: a delivery system for poorly water-soluble drug. Drug Dev. Ind. Pharm. 38, 883-892.
7. Bandivadekar, M., Pancholi, S., Kaul-Ghanekar, R., Choudhari, A., Koppikar, S., in press. Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study. Drug Dev. Ind. Pharm.
8. Beg, S., Swain, S., Singh, H.P., Patra, Ch.N., Rao, M.E., 2012. Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. AAPS PharmSciTech. 13, 1416-1427.
9. Beg, S., Jena, S.S., Patra, Ch.N., Rizwan, M., Swain, S., Sruti, J., Rao, M.E., Singh, B., 2013. Development of solid self-nanoemulsifying granules (SSNEGs) of ondansetron hydrochloride with enhanced bioavailability potential. Colloids Surf. B Biointerfaces 101, 414-423.
10. Bernkop-Schnürch, A., Paikl, C., Valenta, C., 1997. Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm. Res. 14, 917-922. (Pubitemid 27326988)
11. Christiansen, A., Backensfeld, T., Weitschies, W., 2010. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur. J. Pharm. Sci. 41, 376-382.
12. Cone, R., 1999. Mucus. In: Michael, W.S., Lamm, E., Mayer, Lloyd, McGhee, Jerry R., Bienenstock, John, Mestecky, Jiri (Eds.), Mucosal Immunology. Academic Press, San Diego, pp. 43-64.
13. Coupe, A.J., Davis, S.S., Wilding, I.R., 1991. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 8, 360-364.
14. des Rieux, A., Ragnarsson, E.G., Gullberg, E., Préat, V., Schneider, Y.J., Artursson, P., 2005. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25, 455-465. (Pubitemid 40853873)
15. Florence, A.T., 1997. The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm. Res. 14, 259-266. (Pubitemid 27160935)
16. Florence, A.T., Hillery, A.M., Hussain, N., Jani, P.U., 1995. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target. 3, 65-70.
17. Harde, H., Das, M., Jain, S., 2011. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin. Drug Deliv. 8, 1407-1424.
18. Hintzen, F., Laffleur, F., Perera, G., Müller, C., Bernkop-Schnürch, A., 2012. Protection of leuprorelin against enzymatic degradation by a self-microemulsifying drug delivery system (SMEDDS). In: XI International Conference on Nanostructured Materials, Rhodos, Greece.
19. Hu, X., Lin, C., Chen, D., Zhang, J., Liu, Z., Wu, W., Song, H., 2012. Sirolimus solid selfmicroemulsifying pellets: formulation development, characterization and bioavailability evaluation. Int. J. Pharm. 438, 123-133.
20. Hunter, A.C., Elsom, J., Wibroe, P.P., Moghimi, S.M., 2012. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine Suppl. 1, S15-20.
21. Iqbal, J., Sakloetsakun, D., Bernkop-Schnürch, A., 2011. Thiomers: inhibition of cytochrome P450 activity. Eur. J. Pharm. Biopharm. 78, 361-365.
22. Junghanns, J.U., Müller, R.H., 2008. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine 3, 295-309.
23. Lai, S.K., Wang, Y.Y., Hanes, J., 2009. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158-171.
24. Lai, S.K., Wang, Y.Y., Hida, K., Cone, R., Hanes, J., 2010. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc. Natl. Acad. Sci. USA 107, 598-603.
25. Lin, X. et al., 2006. Release-controlling absorption enhancement of enterally administered Ophiopogon japonicus polysaccharide by sodium caprate in rats. J. Pharm. Sci. 95, 2534-2542. (Pubitemid 44726393)
26. Luessen, H.L., de Leeuw, B.J., Langemeÿer, M.W., de Boer, A.B., Verhoef, J.C., Junginger, H.E., 1996. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13, 1668-1672. (Pubitemid 26426890)
27. Müller, C., 2013. Thesis. University of Innsbruck, Austria.
28. Müller, R.H., Gohla, S., Keck, C.M., 2011. State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 78, 1-9.
29. Müller, C., Leithner, K., Hauptstein, S., Hintzen, F., Salvenmoser, W., Bernkop-Schnürch, A., 2013. Preparation and characterization of mucus-penetrating papain/poly(acrylic acid) nanoparticles for oral drug delivery applications. J. Nanopart. Res. 15, 1353.
30. Olmsted, S.S., Padgett, J.L., Yudin, A.I., Whaley, K.J., Moench, T.R., Cone, R.A., 2001. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81, 1930-1937. (Pubitemid 32917145)
31. Rao, S.V., Agarwal, P., Shao, J., 2008a. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int. J. Pharm. 362, 10-15.
32. Rao, S.V., Yajurvedi, K., Shao, J., 2008b. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: III. In vivo oral absorption study. Int. J. Pharm. 362, 16-19.
33. Sparreboom, A., Verweij, J., van der Burg, M.E., Loos, W.J., Brouwer, E., Viganò, L., Locatelli, A., de Vos, A.I., Nooter, K., Stoter, G., Gianni, L., 1998. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin. Cancer Res. 4, 1937-1942. (Pubitemid 28369178)
34. Takeuchi, H., Matsui, Y., Yamamoto, H., Kawashima, Y., 2003. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J. Control. Release 86, 235-242. (Pubitemid 36084273)
35. Thanou, M., Verhoef, J.C., Junginger, H.E., 2001. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50 (Suppl. 1), S91-101.
36. Wahlang, B., Kabra, D., Pawar, Y.B., Tikoo, K., Bansal, A.K., 2012. Contribution of formulation and excipients towards enhanced permeation of curcumin. Arzneimittelforschung 62, 88-93.
37. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D., 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146. (Pubitemid 39361543)
38. Wu, W., Wang, Y., Que, L., 2006. Enhanced bioavailability of silymarin by selfmicroemulsifying drug delivery system. Eur. J. Pharm. Biopharm. 63, 288-294. (Pubitemid 43776222)
39. Zabaleta, V., Ponchel, G., Salman, H., Agüeros, M., Vauthier, C., Irache, J.M., 2012. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur. J. Pharm. Biopharm. 81, 514-523.